342894-91-1

Basic information

• Product Name: 1,4-dimethyl-6-phenethyl-1,2,3,6-tetrahydro-pyridine
• Synonyms: 1,4-dimethyl-6-phenethyl-1,2,3,6-tetrahydro-pyridine
• CAS NO: 342894-91-1
• Molecular Weight: 215.338
• Mol File: 342894-91-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,4-dimethyl-6-phenethyl-1,2,3,6-tetrahydro-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dimethyl-6-phenethyl-1,2,3,6-tetrahydro-pyridine(342894-91-1)
• EPA Substance Registry System: 1,4-dimethyl-6-phenethyl-1,2,3,6-tetrahydro-pyridine(342894-91-1)

Safety Data

• Hazardous Substances Data: 342894-91-1(Hazardous Substances Data)

Upstream product

• 75835-06-2 1,4-dimethyl-2-phenethyl-pyridinium iodide 
• 7433-88-7 4-methyl-2-styryl-pyridine 
• 75835-01-7 methyl-4 (phenyl-2 ethyl)-2 pyridine 
• 75834-96-7 2-(4-methyl(2-pyridyl))-1-phenylethan-1-ol 
• 108-47-4 2,4-lutidine 
• 100-52-7 benzaldehyde 
• 536-74-3 phenylacetylene 
• 4926-28-7 2-Bromo-4-picoline 
• 63731-33-9 4-methyl-2-phenylethynyl-pyridine 

Relevant articles and documents

Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use

The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE

The present invention relates to compounds defined by formula (I), wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.